Literature DB >> 22209699

PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer.

M Katie Conley-LaComb1, Wei Huang1, Shihua Wang2, Dongping Shi1, Young Suk Jung1, Abdo Najy1, Rafael Fridman1, R Daniel Bonfil3, Michael L Cher3, Yong Q Chen4, Hyeong-Reh Choi Kim5.   

Abstract

Platelet-derived growth factor (PDGF) family members are potent growth factors that regulate cell proliferation, migration, and transformation. Clinical studies have shown that both PDGF receptor β (β-PDGFR) and its ligand PDGF D are up-regulated in primary prostate cancers and bone metastases, whereas PDGF B, a classic ligand for β-PDGFR, is not frequently detected in clinical samples. In this study, we examined the role of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) in the regulation of PDGF expression levels using both a prostate-specific, conditional PTEN-knockout mouse model and mouse prostate epithelial cell lines established from these mice. We found an increase in PDGF D and β-PDGFR expression levels in PTEN-null tumor cells, accompanied by a decrease in PDGF B expression. Among Akt isoforms, increased Akt3 expression was most prominent in mouse PTEN-null cells, and phosphatidylinositol 3-kinase/Akt activity was essential for the maintenance of increased PDGF D and β-PDGFR expression. In vitro deletion of PTEN resulted in a PDGF ligand switch from PDGF B to PDGF D in normal mouse prostate epithelial cells, further demonstrating that PTEN regulates this ligand switch. Similar associations between PTEN status and PDGF isoforms were noted in human prostate cancer cell lines. Taken together, these results suggest a mechanism by which loss of PTEN may promote prostate cancer progression via PDGF D/β-PDGFR signal transduction. Copyright Â
© 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209699      PMCID: PMC3349886          DOI: 10.1016/j.ajpath.2011.11.021

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  62 in total

Review 1.  Induction and regulation of epithelial-mesenchymal transitions.

Authors:  B Boyer; A M Vallés; N Edme
Journal:  Biochem Pharmacol       Date:  2000-10-15       Impact factor: 5.858

2.  Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor.

Authors:  Kazuishi Kubota; Chisa Sakikawa; Mutsumi Katsumata; Takemichi Nakamura; Kenji Wakabayashi
Journal:  J Bone Miner Res       Date:  2002-02       Impact factor: 6.741

3.  The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.

Authors:  T Maehama; J E Dixon
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

Review 4.  Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways.

Authors:  Lionel Larue; Alfonso Bellacosa
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

5.  PDGF-D, a new protease-activated growth factor.

Authors:  W J LaRochelle; M Jeffers; W F McDonald; R A Chillakuru; N A Giese; N A Lokker; C Sullivan; F L Boldog; M Yang; C Vernet; C E Burgess; E Fernandes; L L Deegler; B Rittman; J Shimkets; R A Shimkets; J M Rothberg; H S Lichenstein
Journal:  Nat Cell Biol       Date:  2001-05       Impact factor: 28.824

6.  Differential growth factor control of bone formation through osteoprogenitor differentiation.

Authors:  L R Chaudhary; A M Hofmeister; K A Hruska
Journal:  Bone       Date:  2004-03       Impact factor: 4.398

7.  Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.

Authors:  Sun Jin Kim; Hisanori Uehara; Sertac Yazici; Robert R Langley; Junqin He; Rachel Tsan; Dominic Fan; Jerald J Killion; Isaiah J Fidler
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

8.  Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.

Authors:  Paul Mathew; Peter F Thall; Corazon D Bucana; William K Oh; Michael J Morris; Donnah M Jones; Marcella M Johnson; Sijin Wen; Lance C Pagliaro; Nizar M Tannir; Shi-Ming Tu; Anthony A Meluch; Lon Smith; Lorenzo Cohen; Sun-Jin Kim; Patricia Troncoso; Isaiah J Fidler; Christopher J Logothetis
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

Review 9.  Indications for imatinib mesylate therapy and clinical management.

Authors:  François Guilhot
Journal:  Oncologist       Date:  2004

10.  PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration.

Authors:  Nick R Leslie; Xuesong Yang; C Peter Downes; Cornelis J Weijer
Journal:  Curr Biol       Date:  2007-01-23       Impact factor: 10.834

View more
  15 in total

1.  Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer.

Authors:  Abdo J Najy; Joshua J Won; Lisa S Movilla; Hyeong-Reh C Kim
Journal:  Mol Cancer Res       Date:  2012-06-11       Impact factor: 5.852

2.  A critical role of the PTEN/PDGF signaling network for the regulation of radiosensitivity in adenocarcinoma of the prostate.

Authors:  Michael Christensen; Abdo J Najy; Michael Snyder; Lisa S Movilla; Hyeong-Reh Choi Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

Review 3.  Cancer stem cells in breast and prostate: Fact or fiction?

Authors:  Rocío G Sampayo; Mina J Bissell
Journal:  Adv Cancer Res       Date:  2019-06-13       Impact factor: 6.242

4.  Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.

Authors:  Kerstin M Heselmeyer-Haddad; Lissa Y Berroa Garcia; Amanda Bradley; Leanora Hernandez; Yue Hu; Jens K Habermann; Christoph Dumke; Christoph Thorns; Sven Perner; Ekaterina Pestova; Catherine Burke; Salim A Chowdhury; Russell Schwartz; Alejandro A Schäffer; Pamela L Paris; Thomas Ried
Journal:  Am J Pathol       Date:  2014-08-14       Impact factor: 4.307

5.  The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.

Authors:  Peter Paximadis; Abdo J Najy; Michael Snyder; Hyeong-Reh Kim
Journal:  Prostate       Date:  2016-01-06       Impact factor: 4.104

6.  Stable expression of human VDR in murine VDR-null cells recapitulates vitamin D mediated anti-cancer signaling.

Authors:  Meggan E Keith; Erika LaPorta; JoEllen Welsh
Journal:  Mol Carcinog       Date:  2013-05-16       Impact factor: 4.784

Review 7.  Emerging roles of PDGF-D in EMT progression during tumorigenesis.

Authors:  Qiong Wu; Xin Hou; Jun Xia; Xiujuan Qian; Lucio Miele; Fazlul H Sarkar; Zhiwei Wang
Journal:  Cancer Treat Rev       Date:  2012-12-20       Impact factor: 12.111

8.  PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.

Authors:  M Katie Conley-LaComb; Allen Saliganan; Pridvi Kandagatla; Yong Q Chen; Michael L Cher; Sreenivasa R Chinni
Journal:  Mol Cancer       Date:  2013-07-31       Impact factor: 27.401

Review 9.  Targeting the PDGF signaling pathway in tumor treatment.

Authors:  Carl-Henrik Heldin
Journal:  Cell Commun Signal       Date:  2013-12-20       Impact factor: 5.712

10.  Neem leaf extract inhibits mammary carcinogenesis by altering cell proliferation, apoptosis, and angiogenesis.

Authors:  Arunkumar Arumugam; Pamela Agullo; Thiyagarajan Boopalan; Sushmita Nandy; Rebecca Lopez; Christina Gutierrez; Mahesh Narayan; Lakshmanaswamy Rajkumar
Journal:  Cancer Biol Ther       Date:  2013-10-21       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.